Search
Date and Time
Thursday, January 18, 2018
6:00 PM – 8:30 PM


Location

The Westin Philadelphia Hotel
99 South 17th Street
Philadelphia, PA 19103
Click Here for a map

Activity Co-Chairs
Stefan Barta, MD, MS, MRCP (pictured top)
Fox Chase Cancer Center / Temple Health


Ubaldo Martinez-Outschoorn, MD (pictured bottom)
Thomas Jefferson University

Register online here

Stefan Barta, MD Ubaldo Martinez-Outschoorn, MD

Please note: Only representatives from supporting pharmaceutical companies are invited to register. If your company is interested in becoming a Lymphoma Rounds supporter please contact Piper Harmon, pharmon@lymphoma.org. Exhibit opportunities are also available, however, space is limited.

Program Agenda

6:00 PM Registration and Networking Dinner Reception

6:45 PMWelcome Piper Harmon, Lymphoma Research Foundation

7:00 PMA Patient with Transformed Lymphoma and MYC Rearrangement Yang Liu, MD, Fox Chase Cancer Center / Temple Health

Moderator
Stefan Barta, MD, MS, MRCP, Fox Chase Cancer Center / Temple Health


7:30 PM T-Cell Lymphoma
Saritha Kartan, MD, Thomas Jefferson University

Moderator

Ubaldo Martinez-Outschoorn, MD, Thomas Jefferson University

8:00 PM First-Line Therapy in Young, Fit Patients with CLL
Gina Keiffer, MD, Thomas Jefferson University

Moderator

Frederick Fellin, MD, Thomas Jefferson University

8:30 PM Adjourn


Register Online
 Here


2017-18 Philadelphia Lymphoma Rounds Series –
Tuesday, October 10, 2017
Thursday, January 18, 2018
Thursday, April 5, 2018

About the Program

The Lymphoma Research Foundation's Philadelphia Lymphoma Rounds program provides a forum for healthcare professionals to meet on a regular basis and address issues specific to the diagnosis and treatment of their lymphoma patients. Participants will network, share best practices and learn the latest information on new therapies and advances in the management of lymphoma through interactive case studies presented by lymphoma experts in the Philadelphia area.

At the conclusion of this educational activity, the participant should be better able to:

  • Summarize the latest developments in lymphoma diagnosis, treatment and management.
  • Apply best practices for treating lymphoma patients.
  • Inform patients about potential clinical trial opportunities.
  • Establish a network of health care professionals who work with lymphoma patients.

Additional Information
This program is free for healthcare professionals; however, pre-registration is required. Food and refreshments will be provided for all registered participants.


Philadelphia Lymphoma Rounds Steering Committee

Cooper University Hospital
Andres Ferber, MD
Fox Chase Cancer Center / Temple University Health System
Stefan Barta, MD, MS, MRCP (UK)
Hackensack University Medical Center
Tatyana Feldman, MD
Thomas Jefferson University
Ubaldo Martinez-Outschoorn, MD
University of Pennsylvania
Anthony Mato, MD, MSCE
Stephen Schuster, MD (chair)
Vita Medical Associates, PC
Anna Niewiarowska, MD

Sponsors






This activity is supported by educational grants from:

AbbVie, Celgene, Genentech, Juno Therapeutics, Kite Pharma, Pharmacyclics LLC and Janssen Biotech, Inc., Seattle Genetics, Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries, LTD and TG Therapeutics

Joint Providership Statement

This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and the Lymphoma Research Foundation.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Statement

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.